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T lymphocytes present in allergically inflamed tissue synthe-
size and secrete the cytokines interleukin (IL)-3, IL-4, IL-5, 
and granulocyte/macrophage colony-stimulating factor 
(GM-CSF). IL-3, IL-5, and GM-CSF, but also IL-4, may act 
as a chemotaxin on eosinophils. In contrast to the former 
cytokines, IL-4 is only chemotactic for eosinophils from the 
peripheral blood of patients with atopic dermatitis and not 
for eosinophils from normal individuals. IL-4 has the same 
chemotactic potency as the other cytokines. The optimal 
chemotactic potency is reached at a concentration of 10 nM. 
In contrast, neutrophils do not respond chemotactically to 
IL-4. Checkerboard analysis, inhibition studies with mono-
A topic dermatitis is considered a T -cell- mediated dis-order [1] . Both T cells in the circulation and within the tissue are in an activated stage [2.3]. Although hardly any intact eosinophils are present in lesional atopic dermatitis skin. deposits of eosinophil-derived 
granules can be observed [4.5]. In non-Iesional atopic dermatitis 
skin. an eczematous skin reaction may be induced after patch testing 
the skin with allergen [6]. The patch test reaction shows macro-
scopic and microscopic resemblance with active lesional atopic der-
matitis skin [5,6]. Six hours after patch testing, eosinophils and T 
cells already start to infiltrate the skin. Macroscopically, an eczema-
toUS reaction takes place 24-48 h after patch testing. At this time-
point, T cells and eosinophils appear in an activated stage, with 
some of the T cells being CD4 positive, exactly as in lesional atopic 
dermatitis skin. T-cell clones derived from biopsies from active 
lesional skin and from biopsies taken 24 h after patch testing non-
lesional atopic dermatitis skin have indicated that these T cells syn-
thesize and secrete various cytokines [7]. The most important cyto-
kines in this respect are interleukin (IL)-3, IL-4, IL-S. and 
granulocyte-macrophage colony stimulating factor (GM-CSF). Be-
cause these T cells produce both IL-4 and IL-5, they are considered 
to be of the Th2 phenotype [8]. 
IL-4 has many biologic activities and cellular targets. It was origi-
nally described as a costimulant of B cells [9]. Other effects on B 
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clonal anti - IL-4 antibodies, and desensitization experiments 
indicated specific interaction of IL-4 with eosinophils. In 
eosinophils from normal individuals, IL-4 responsiveness 
could be induced by pretreatment of the cells with IL-5 and 
GM-CSF. In addition to the fact that IL-4 may be responsible 
for selective eosinophil transendothelial migration, IL-4 may 
exert an important modulatory mode of action on eosinophil 
migration and function within allergically inflamed tissue. 
Our findings suggest the presence of a functional IL-4R on 
eosinophils from atopic dermatitis patients. Key words: atopic 
dermatitis/cytokines/eosinophils/migration/interleu kin 4. ] f'lllest 
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lyn~phocytes include induction of class II major histocompatibility 
antlgens [10] and induction of FCERII [11,12]. AdditionaHy, IL-4 
induces the proliferation of human thymocytes and primary mast 
cells [1 ~]. It also enhances the immunoglobulin (Ig)E and IgG 1 
production [14] and influences tumor-infiltrating lymphocytes and 
lymphokine-activated killer cells [15]. IL-4 has also been reported 
to act as a chemotaxin for fibroblasts [16]. 
Here w.e report .tl:at IL-4 acts chemotactically on eosinophils 
from atopic dermatltls patients but not on those from normal indi-
viduals. IL-4 possesses almost the same chemotactic potency as IL-3, 
IL-5, and GM-CSF. These findings therefore further extend the 
importance of IL-4 for the pathogenesis of allergic inflammation. 
MATERIALS AND METHODS 
Subjects . AI~ pa~ients (17 women and 23 men between 21 and 42 years of 
age) p~rtl~lpatlllg III this study had atoric dermatitis as classified accord. ing to 
the . c:lte~la of Hamfin and Rajka [17 . They all were allergic. i.e., showed 
positive mtracutaneous skin reactions to three or more different allergens, 
havlllg elevated total IgE levels and positive radio-allergo-sorbent tests for 
the relevant allergens. The patients had not taken oral steroids for at least 2 
weeks be.fore the study. All patients had increased blood eosinophilia. They 
had received only small amounts of topically applied steroids. All other 
therapr was abando?ed at least 2 weeks before the study. At the time of blood 
collection most patients had moderate to mild eczema; active lesions were 
present on predilection sites. All patients had elevated blood eosinophil 
levels (m~re than 4%). The normal healthy volunteers were not allergic. did 
not have mcreased blood eosinophilia, and did not take any kind of medica-
tion. All participating individuals gave their informed consent. 
Reagents Ficoll-Paque and Percoll were obtained from Pharmacia 
(Uppsala, Sweden). All experiments were carried out in N-2-hydroxyethyl-
piperazine-N'-2-cthanesulfonic acid (HEPES) buffer containing 132 mM 
NaCI.6 rnM KCI , 1 mM CaCl2 , 1 mM MgSO., 1.2 mM potassium phos-
phate. 20 mM HEPES, S mM glucose, and 1.0% HSA (wt/vol), pH 7.4. 
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Cytokines Recombinant human GM-CSF (11.5 X 10' U/mg) and IL-3 
(3 X 10' U/mg) were a kind gift from Dr. G. Zenke (Sandoz Ltd., Basel, 
Switzerland) . Recombinant human IL-4 was a kind gift of Dr. A. Stutz 
(Sandoz Forschungsinstitut, Vienna, Austria) . Recombinant human IL-5 
(4 X 105 U/ml) was a kind gift of Dr. c.]. Sanderson (National Institute for 
Medical Research, London, UK). The molarity of this IL-5 preparation was 
determined by comparison of its potency with commercially avai lable 
rhIL-5 (Amersham, Buckinghamshire, UK; 106 U /mg). Stock solutions of 
the cytokines were prepared in phosphate-buffered salt solution supple-
mented with 0.1% purified human albumin, and were stored at -70·C 
until use. 
Monoclonal Antibodies Anti-human GM-CSF monoclonal antibody 
(MoAb) (mouse IgGl) was a kind gift from Dr. G. Zenke (Sandoz Ltd, Basel, 
Switzerland) . Anti-human IL-4 MoAb (mouse IgGl) was a kind gift from 
Dr. F. Kalthoff (Sandoz Ltd, Vienna, Austria). Anti-human rhIL-5 MoAb 
(mouse IgGl), neutralizing 400 U/m! rhIL-5 at a concentration of 16 
fig/ml, was a kind gift from Dr. J. Tavernier (Roche Research, Gent, 
Belgium). 
Cell Isolation Blood was obtained from healthy volunteers or from 
atopic dermatitis patients. Eosinophils from the blood of normal donors 
were isolated from the buffy coat of 500 ml of blood and eosinophils from 
the patients were isolated from 50 ml of blood anticoagulated with 0.4% 
(wt/vol) trisodium citrate (pH 7.4) as described before (18). Eosinophil 
purity was always> 95% and the viability was over 98%. 
Migration Assay For the microchemotaxis assay, migration was mea-
sured with a modified Boyden chamber assay using a 48-well microchemo-
taxis chamber (Neuroprobe, Cabin John, MD), exactly as described before 
[18]. The number of cells per 10 high-power fields (hpf) was determined 
with light microscopy (magnification 400 X). In this way the number of 
cells that had passed the upper filter was determined. 
Statistical Analysis All data are presented as mean ± SEM. The Student 
t test for paired or unpaired data was applied. p < 0.05 was considered 
significant. 
RESULTS 
The Migratory Responsiveness of Eosinophils from the 
Circulation of Normal Individuals and Atopic Dermatitis 
Patients Toward IL-4 We examined the ability ofIL-4 to mobi-
lize eosinophils using a modified Boyden chamber assay. As de-
picted in Fig lA, eosinophils from atopic dermatitis showed a dose-
dependent migratory response toward IL-4. At the highest IL-4 
concentration used (10 nM), the magnitude of the observed migra-
tory response almost equalled that of the platelet-activating factor 
(PAF)-induced migratory response at 10 nM [18] . In contrast, eo-
sinophils from normal individuals showed no significant migratory 
response toward IL-4. 
Having observed that IL-4 induces migration of eosinophils from 
atopic dermatitis patients and not from normal individuals, we also 
investigated the cell specificity of the action of IL-4 on migration. 
As depicted in Fig lB, IL-4 does not induce a migratory response of 
neutrophils from both atopic dermatitis patients and normal indi-
viduals. Therefore, IL-4 seems to act specifically on eosinophils 
from atopic dermatitis patients. 
Checkerboard Analysis To investigate whether the IL-4-
induced migratory response was due to chemotaxis or chemokine-
sis, checkerboard analysis was performed. The checkerboard analy-
sis revealed that IL-4 acts as a chemotaxin on eosinophils from 
atopic dermatitis patients and that the effect on the chemokinesis of 
eosinophils can be neglected (see Table I). 
Specificity of the IL-4-Induced Chemotaxis The IL-4-
induced chemotactic response of eosinophils from the circulation of 
atopic dermatitis patients could be strongly inhibited by a specific 
monoclonal antibody (Fig 2) . The inhibition was cytokine specific, 
because the antibody could not inhibit the chemotactic response 
towards other cytokines (data not shown). Desensitization experi-
ments with rhIL-4 also showed a specific interaction between IL-4 
and the eosinophils (Fig 3). 
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Figure 1. Migratoty responses of eosinophils (A) and neutrophils (B) from 
the circulation of atopic dermatitis patients (open circle) or normal individuals 
(solid circle) toward dose ranges of IL-4. Mean values ± SEM are presented 
for n = 11 (normal individuals) and n = 15 (atopic dermatitis patients) ex-
periments for eosinophils and n = 4 (normal individuals) and n = 7 (atopic 
dermatitis patients) experiments for neutrophils. Asterisk, values differ sig-
nificantly from the corresponding values obtained with normal individuals 
(p < 0.05; unpaired Student t test). 
Comparison of Chemotactic Potency of IL-4 with Other 
Chemotaxins Table II shows a comparison of the chemotactic 
potency of IL-4 with other chemotaxins for eosinophils from the 
circulation of normal individuals and atopic dermatitis patients. As 
can be seen, IL-4 possesses a chemotactic potency similar to that of 
IL-3, IL-S, IL-8, and GM-CSF for eosinophils from atopic dermati-
tis patients. 
Induction of IL-4 Chemotactic Response by GM-CSF and 
IL-5 To see whether the difference between the migratory re-
sponse of eosinophils from normal individuals and atopic dermatitis 
patients was due to previous in vivo contact of the eosinophils from 
atopic dermatitis patients with GM-CSF or IL-S, experiments were 
performed with eosinophils from normal individuals that had been 
incubated overnight with 10 pM GM-CSF or IL-S. Indeed, eosino-
phils that had been pretreated with these cytokines and washed 
Table I. Checkerboard Analysis of IL-4 - Induced Chemotaxis 
of Eosinophils from Atopic Dermatitis Patients' 
Upper Lower Compartment IL-4 
Compartment 
IL-4 0 1.2510-9 2.510-9 5.010-9 1010-9 
0 23 ± 8 36 ± 10 63 ± 8 78 ± 7 108 ± 8 
1.25 10-9 22±5 22±3 32 ± 6 52 ± 12 72±9 
2.510-9 21 ± 4 25 ± 8 25 ± 3 44 ± 12 62± 10 
5.010-9 23 ± 7 21 ± 2 20±3 25±2 44±9 
10 10-9 24±4 26±6 28 ± 5 25 ± 9 23 ± 3 
• Different IL-4 preparations were used in the upper and lower compartment of the 
modified Boyden chamber. The resu lts arc expressed as the number of eosinophils/10 
high-power fields (hpf). Mean values ± SEM for four different experiments are 
presented. 
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Figure 2. Inhibition of IL-4 - induced chemotaxis by a specific monoclonal 
antibody against rhIL-4. Mean values ± SEM of four different experiments 
are presented. 
thereafter became responsive towards IL-4. This is illustrated for 
GM-CSF in Fig 4. IL-s gave exactly the same results (data not 
shown). This priming could be inhibited with neutralizing anti-
bodies for about 80% (mean of n = 4 different experiments) . Prein-
cubation of eosinophils from atopic dermatitis patients overnight 
with GM-CSF or IL-s did not result in a significant increase of the 
IL-4 responsiveness (data not shown). The responsiveness towards 
the lower IL-4 concentrations (1-10 pM) slightly increased, but 
the maximal observed migratory response did not significantly in-
crease. The fact that the overall increase was not significant was due 
mainly to an increase in the random migration (chemokinesis). 
DISCUSSION 
The eosinophil is recognized as an important effector cell capable of 
contributing to the pathogenesis of allergic inflammation. How-
ever, the recruitment and function of eosinophils is strongly depen-
dent upon the production and secretion of cytokines by other cell 
types, e.g., T cells. 
Here we show that IL-4 is chemotactic for eosinophils from 
patients with atopic dermatitis but not for eosinophils from normal 
individuals. In recent years we have concentrated on the question of 
how eosinophils can selectively migrate into the tissue, in particu-
lar, in case of allergic inflammatory reactions [18,19). So far, these 
investigations have indicated that eo sino phi Is in the circulation 
from atopic dermatitis patients are in a "primed" state. O ther stud-
ies showed that the migratory response of eosinophils from normal 
individuals could be increased by pretreatment of those cells with 
IL-3, IL-s, or GM-CSF. Pretreatment with these cytokines resulted 
in the induction of a migratory response towards neutrophil activat-
ing factor (NAF)/IL-8 and N-formyl-methionyl-leucyl-phenylala-
nine (fMLP) [20) . Here we show that GM-CSF and IL-s are capable 
of inducing a migratory response of eosinophils from normal indi-
viduals toward IL-4. Therefore, these findings extend the evidence 
that eosinophils from the circulation of patients with allergic disor-
ders are "primed" i" vivo, most likely due to previous contact with 
the cytokines IL-3, IL-s, or GM-CSF. 
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Figure 3. Desensitization ofIL-4-induced migration of eosinophils from 
aropic dermatitis patients. Eosinophils were preincubated overnight at 37 0 C 
With buffer (solid circle) or rhIL-4 (Opfll circle), washed, and then the IL-4-
induced chemotaxis was measured. Mean values ± SEM of four different 
experiments are presented. Asterisk, values differ significantly from the 
corresponding values obtained before preincubation (p < 0.05; paired Stu-
dent t test) . 
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Table II. Comparison of IL-4 - Induced Chemotaxis of 
Eosinophils from the Circulation of Normal Individuals and 
Atopic Dermatitis Patients with Other Chemotaxins 
Cells per 10 hpf 
Optimal 
(mean values ± SEM) 
Chemotactic Atopic 
Chemotaxin Concentration Normals Dermatitis 
Buffer 24 ± 5 (12)< 24 ± S (8) 
IL-3 10 nM 50 ± 8 (8) 90 ± l Sb (8) 
IL-S 10 nM 70±1S(8) 90 ± lOb (8) 
GM-CSF 10nM 80 ± 11 (8) 60 ± 9 (8) 
1 nM' SO± 10 (8) 100 ± 9b (8) 
IL-8 10nM 21 ± 4 (8) 71 ± 19 (8) 
TNFa 10nM 3S ± 7 (8) 3S ± 7 (8) 
IL-4 10 nM 29 ± 6 (11) 83 ± 8b (14) 
: Optimal, co~ccntrat.ion for eosinophils from atopic dermatitis patients. 
Differs S1gruficantly from the control values (p < 0.05; unpaired Student t test). 
, In parentheses, number of experiments. 
The presence of activated T cells in the circulation and tissue of 
at?pic dermatitis patients, which, according to their phenotype, 
Will secrete IL-4 in addition to the priming cytokines IL-3, IL-s, 
and GM-CSF, allows the suggestion that IL-4 may contribute to 
t~s~ue r~cruitment of eosinophils. Skin biopsies from atopic derma-
tltlS patlents showed increased levels of mRNA for both IL-4 and 
!L-s [Kilgus 0 et a/: (abstr)] In vest Dermato/100:489 , 1993). This is 
111 contrast to the skin of normal individuals, where hardly any 
mRNA for these cytokines can be detected. In addition, the pres-
ence of IL~4 in lesional atopic dermatitis skin was directly demon-
strated b):' llI~tnunocytochemical staining (Dr. T. Thepen, personal 
commul1lcatlon). 
Transendothelial migration of eosinophils into the tissue in-
v.olves a cu?,ulative series of interactions in which eosinophil adhe-
5111S , adheSIOn molecules on endothelial cells, and the activity of 
many chemoattractants playa crucial role. Most of these chemoat-
tracta.nts lack singular specificity for eosinophils and therefore it is 
questlonable to what extent they contribute in vivo to the accumula-
~ion of eosinophils in the tissue. In this respect, IL-4 can be an 
Impo~tant cytokine. IL-4 can induce the expression of vascular cell 
a?heslOn ?,0Iecul.e-1 on endothelial cells [21) . Through the expres-
sl~n of thiS adheSIOn structure it allows eosinophils to attach to and 
ml~rate through the endothelium [22). Eosinophils, but not neutro-
phlls, do exp~ess the counterpart structure of vascular cell adhesion 
molecule-1, I.e., very late antigen-4 [23). 
Taken together, this study shows that IL-4 not only plays an 
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Figure 4. Induction of IL-4 - induced chemotactic response of eosinophils 
by GM-CSF from normal individuals. Eosinophils were incubated overnight 
With 10 pM GM-CSF. The chemotactic response of these eosinophi ls (opw 
circle) was compared with untreated eosinophils (solid circle) . Mean values ± 
S.EM are presented for four different experiments. Asterisk, values differ 
slgmficantly from the corresponding va lues obtained before preincubation 
(p < 0.05; paired Student t test) . 
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important role in the selective eosinophil extravasation but could 
also contribute to the directed migration of eosinophils within the 
tissue. Furthermore, our findings suggest the presence of a func-
tional IL-4R on eosinophils from atopic dermatitis patients. This is 
currently under investigation. 
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